$2.23
3.88% today
Nasdaq, Apr 04, 07:53 pm CET
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Evoke Pharma, Inc. Stock price

$2.32
-1.30 35.98% 1M
-2.88 55.38% 6M
-2.10 47.51% YTD
-5.12 68.82% 1Y
-61.04 96.34% 3Y
-148.88 98.47% 5Y
-1,047.44 99.78% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.27 10.42%
ISIN
US30049G1040
Symbol
EVOK
Sector
Industry

Key metrics

Market capitalization $3.46m
Enterprise Value $-4.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.91
EV/Sales (TTM) EV/Sales -0.49
P/S ratio (TTM) P/S ratio 0.34
P/B ratio (TTM) P/B ratio 0.49
Revenue growth (TTM) Revenue growth 97.84%
Revenue (TTM) Revenue $10.25m
EBIT (operating result TTM) EBIT $-5.20m
Free Cash Flow (TTM) Free Cash Flow $-5.46m
Cash position $13.60m
EPS (TTM) EPS $-4.76
P/S forward 0.22
EV/Sales forward negative
Short interest 1.41%
Show more

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Evoke Pharma, Inc.:

Buy
100%

Financial data from Evoke Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10 10
98% 98%
100%
- Direct Costs 0.36 0.36
80% 80%
4%
9.89 9.89
99% 99%
96%
- Selling and Administrative Expenses 15 15
23% 23%
147%
- Research and Development Expense - -
-
-
-5.20 -5.20
30% 30%
-51%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.20 -5.20
30% 30%
-51%
Net Profit -5.35 -5.35
31% 31%
-52%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Negative
Proactive Investors
9 days ago
Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025.  Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year.
Neutral
Seeking Alpha
22 days ago
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Daniel Kontoh-Boateng – DKB Partners Matt D'Onofrio – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, GIMOTI, EVERSANA Mark Kowieski – Chief Financial Officer Conference Call Participants Yale Jen – Laidlaw & Company Operator Good afternoon, and welcome to the ...
Neutral
GlobeNewsWire
22 days ago
Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an awa...
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Matthew D'Onofrio
Employees 3
Founded 2007
Website www.evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today